AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis Corrigendum in /10.3892/or.2017.5482

Choi,Yun  Jung; Kim,Ji  Hye; Rho,Jin  Kyung; Kim,Joong  Sun; Choi,Chang-Min; Kim,Woo  Sung; Son,Jaekyoung; Lee,Jae  Cheol

doi:10.3892/or.2017.5482

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis

Corrigendum in: /10.3892/or.2017.5482

Authors:
- Yun Jung Choi
- Ji Hye Kim
- Jin Kyung Rho
- Joong Sun Kim
- Chang-Min Choi
- Woo Sung Kim
- Jaekyoung Son
- Jae Cheol Lee
View Affiliations

Affiliations: Asan Institute for Life Sciences, Asan Medical Center, College of Medicine, University of Ulsan, Seoul 138-736, Republic of Korea, Department of Biomedical Sciences, College of Medicine, University of Ulsan, Seoul 138-736, Republic of Korea, Dongnam Institute of Radiological and Medical Sciences (DIRAMS), Busan 619-953, Republic of Korea, Department of Oncology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul 138-736, Republic of Korea, Department of Pulmonology and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul 138-736, Republic of Korea
Published online on: March 1, 2017 https://doi.org/10.3892/or.2017.5482
Pages: 2201-2208

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The AXL and MET receptors regulate key processes in tumor growth, metastasis, and drug resistance; thus, they have recently been implicated as promising therapeutic targets in various tumors. We investigated the metastatic potential and crosstalk between these receptors in non‑small cell lung cancer (NSCLC). We found that the treatment of NSCLC cells with hepatocyte growth factor (HGF) and growth arrest-specific 6 (Gas6), as ligands for MET and AXL, respectively, promoted their migration and invasion ability. However, treatment with inhibitors of each of these receptors significantly reduced the migratory and invasiveness of the cells, although their inhibitory rates varied according to the inhibition of each receptor. In addition, the suppression of each receptor by shRNA resulted in reduced migration and invasiveness. Notably, the suppression of AXL was more effective than the suppression of MET in the inhibition of migration and invasion. In accordance with in vitro results, when the cells were transferred via tail vein injection, AXL inhibition was more efficient in attenuating metastasis than MET inhibition. Clinically, AXL or MET expression is associated with a poor prognosis in primary tumors of NSCLC. In summary, AXL and MET can regulate tumor metastasis, but AXL was shown to be more potent than MET in lung metastasis. Thus, we conclude that AXL might be a suitable therapeutic target for the inhibition of lung metastasis.

View Figures

View References

1	Robinson DR, Wu YM and Lin SF: The protein tyrosine kinase family of the human genome. Oncogene. 19:5548–5557. 2000. View Article : Google Scholar : PubMed/NCBI
2	Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell. 103:211–225. 2000. View Article : Google Scholar : PubMed/NCBI
3	Krause DS and Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med. 353:172–187. 2005. View Article : Google Scholar : PubMed/NCBI
4	Hafizi S and Dahlbäck B: Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev. 17:295–304. 2006. View Article : Google Scholar : PubMed/NCBI
5	Linger RM, Keating AK, Earp HS and Graham DK: TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 100:35–83. 2008. View Article : Google Scholar : PubMed/NCBI
6	Manfioletti G, Brancolini C, Avanzi G and Schneider C: The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol. 13:4976–4985. 1993. View Article : Google Scholar : PubMed/NCBI
7	Schneider C, King RM and Philipson L: Genes specifically expressed at growth arrest of mammalian cells. Cell. 54:787–793. 1988. View Article : Google Scholar : PubMed/NCBI
8	Goruppi S, Ruaro E and Schneider C: Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene. 12:471–480. 1996.PubMed/NCBI
9	Berclaz G, Altermatt HJ, Rohrbach V, Kieffer I, Dreher E and Andres AC: Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol. 12:819–824. 2001. View Article : Google Scholar : PubMed/NCBI
10	Craven RJ, Xu LH, Weiner TM, Fridell YW, Dent GA, Srivastava S, Varnum B, Liu ET and Cance WG: Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer. 60:791–797. 1995. View Article : Google Scholar : PubMed/NCBI
11	Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N, Knyazeva T, Barbieri V, Reindl M, Muigg A, et al: Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res. 14:130–138. 2008. View Article : Google Scholar : PubMed/NCBI
12	Quong RY, Bickford ST, Ing YL, Terman B, Herlyn M and Lassam NJ: Protein kinases in normal and transformed melanocytes. Melanoma Res. 4:313–319. 1994. View Article : Google Scholar : PubMed/NCBI
13	Sawabu T, Seno H, Kawashima T, Fukuda A, Uenoyama Y, Kawada M, Kanda N, Sekikawa A, Fukui H, Yanagita M, et al: Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog. 46:155–164. 2007. View Article : Google Scholar : PubMed/NCBI
14	Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS and Wu CW: Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia. 7:1058–1064. 2005. View Article : Google Scholar : PubMed/NCBI
15	Brand-Saberi B, Müller TS, Wilting J, Christ B and Birchmeier C: Scatter factor/hepatocyte growth factor (SF/HGF) induces emigration of myogenic cells at interlimb level in vivo. Dev Biol. 179:303–308. 1996. View Article : Google Scholar : PubMed/NCBI
16	Hattori S, Kikuchi E, Kosaka T, Miyazaki Y, Tanaka N, Miyajima A, Mikami S and Oya M: Relationship between increased expression of the Axl/Gas6 signal cascade and prognosis of patients with upper tract urothelial carcinoma. Ann Surg Oncol. 23:663–670. 2016. View Article : Google Scholar : PubMed/NCBI
17	Reichl P, Dengler M, van Zijl F, Huber H, Führlinger G, Reichel C, Sieghart W, Peck-Radosavljevic M, Grubinger M and Mikulits W: Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma. Hepatology. 61:930–941. 2015. View Article : Google Scholar : PubMed/NCBI
18	Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, et al: AXL is a logical molecular target in head and neck squamous cell carcinoma. Clin Cancer Res. 21:2601–2612. 2015. View Article : Google Scholar : PubMed/NCBI
19	Dunne PD, McArt DG, Blayney JK, Kalimutho M, Greer S, Wang T, Srivastava S, Ong CW, Arthur K, Loughrey M, et al: AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin Cancer Res. 20:164–175. 2014. View Article : Google Scholar : PubMed/NCBI
20	Lee HJ, Jeng YM, Chen YL, Chung L and Yuan RH: Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis. 35:769–775. 2014. View Article : Google Scholar : PubMed/NCBI
21	Debruyne DN, Bhatnagar N, Sharma B, Luther W, Moore NF, Cheung NK, Gray NS and George RE: ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT. Oncogene. 35:3681–3691. 2016. View Article : Google Scholar : PubMed/NCBI
22	Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ and Leedman PJ: Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther. 12:2541–2558. 2013. View Article : Google Scholar : PubMed/NCBI
23	Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
24	Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Foppen Geukes MH, et al: Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 5:57122014. View Article : Google Scholar : PubMed/NCBI
25	Heymann S, Koudrova M, Arnold H, Köster M and Braun T: Regulation and function of SF/HGF during migration of limb muscle precursor cells in chicken. Dev Biol. 180:566–578. 1996. View Article : Google Scholar : PubMed/NCBI
26	Borowiak M, Garratt AN, Wüstefeld T, Strehle M, Trautwein C and Birchmeier C: Met provides essential signals for liver regeneration. Proc Natl Acad Sci USA. 101:10608–10613. 2004. View Article : Google Scholar : PubMed/NCBI
27	Huh CG, Factor VM, Sánchez A, Uchida K, Conner EA and Thorgeirsson SS: Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA. 101:4477–4482. 2004. View Article : Google Scholar : PubMed/NCBI
28	Di Renzo MF, Poulsom R, Olivero M, Comoglio PM and Lemoine NR: Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. 55:1129–1138. 1995.PubMed/NCBI
29	Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Woude GF Vande, et al: C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 113:678–682. 2005. View Article : Google Scholar : PubMed/NCBI
30	Liu C, Park M and Tsao MS: Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene. 7:181–185. 1992.PubMed/NCBI
31	Ramirez R, Hsu D, Patel A, Fenton C, Dinauer C, Tuttle RM and Francis GL: Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol (Oxf). 53:635–644. 2000. View Article : Google Scholar : PubMed/NCBI
32	Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon SJ, Park BM, Park E, Bae JH, Choi CM, et al: MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res. 74:253–262. 2014. View Article : Google Scholar : PubMed/NCBI
33	Tokunou M, Niki T, Eguchi K, Iba S, Tsuda H, Yamada T, Matsuno Y, Kondo H, Saitoh Y, Imamura H, et al: c-MET expression in myofibroblasts: Role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol. 158:1451–1463. 2001. View Article : Google Scholar : PubMed/NCBI
34	Tsao MS, Liu N, Chen JR, Pappas J, Ho J, To C, Viallet J, Park M and Zhu H: Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer. 20:1–16. 1998. View Article : Google Scholar : PubMed/NCBI
35	Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, et al: Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65:1479–1488. 2005. View Article : Google Scholar : PubMed/NCBI
36	Wimmel A, Glitz D, Kraus A, Roeder J and Schuermann M: Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer. 37:2264–2274. 2001. View Article : Google Scholar : PubMed/NCBI
37	Salian-Mehta S, Xu M and Wierman ME: AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival. Mol Cell Endocrinol. 374:92–100. 2013. View Article : Google Scholar : PubMed/NCBI
38	Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK and Lee JC: Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol. 7:1093–1102. 2013. View Article : Google Scholar : PubMed/NCBI
39	Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, Kallop D, Ludlam MJ and Pei L: Axl as a potential therapeutic target in cancer: Role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 28:3442–3455. 2009. View Article : Google Scholar : PubMed/NCBI
40	Organ SL and Tsao MS: An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 3:(Suppl). S7–S19. 2011. View Article : Google Scholar : PubMed/NCBI
41	Sierra JR and Tsao MS: c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 3:(Suppl). S21–S35. 2011. View Article : Google Scholar : PubMed/NCBI
42	Gujral TS, Karp RL, Finski A, Chan M, Schwartz PE, MacBeath G and Sorger P: Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene. 32:3470–3476. 2013. View Article : Google Scholar : PubMed/NCBI
43	Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
44	Freudlsperger C, Alexander D, Reinert S and Hoffmann J: Prognostic value of c-Met expression in oral squamous cell carcinoma. Exp Ther Med. 1:69–72. 2010.PubMed/NCBI
45	Gisterek I, Lata E, Halon A, Matkowski R, Szelachowska J, Biecek P and Kornafel J: Prognostic role of c-met expression in breast cancer patients. Rep Pract Oncol Radiother. 16:173–177. 2011. View Article : Google Scholar : PubMed/NCBI
46	Ishikawa M, Sonobe M, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N and Date H: Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients. Ann Surg Oncol. 20:(Suppl 3). S467–S476. 2013. View Article : Google Scholar : PubMed/NCBI
47	Lee CH, Yen CY, Liu SY, Chen CK, Chiang CF, Shiah SG, Chen PH and Shieh YS: Axl is a prognostic marker in oral squamous cell carcinoma. Ann Surg Oncol. 19:(Suppl 3). S500–S508. 2012. View Article : Google Scholar : PubMed/NCBI
48	Pinato DJ, Mauri FA, Lloyd T, Vaira V, Casadio C, Boldorini RL and Sharma R: The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma. Br J Cancer. 108:621–628. 2013. View Article : Google Scholar : PubMed/NCBI